|1.||Portugal, José: 1 article (11/2003)|
|2.||Sekine, Tomohisa: 1 article (06/2002)|
|3.||Takashima, Shigemitsu: 1 article (06/2002)|
|4.||Yamamoto, Nobuyuki: 1 article (06/2002)|
|5.||Tominaga, Takeshi: 1 article (06/2002)|
|6.||Kimura, Morihiko: 1 article (06/2002)|
|7.||Nomura, Yasuo: 1 article (06/2002)|
|8.||Shin, Eisei: 1 article (06/2002)|
|9.||Toi, Masakazu: 1 article (06/2002)|
|10.||Nishiyama, Kiyoshi: 1 article (06/2002)|
11/01/2003 - "IST-622 (6-O-(3-ethoxypropylonyl)-3',4'-O-exo-benzylidene-chartreusin), a novel semi-synthetic derivative of chartreusin, which has shown a promising anti-cancer activity in a phase II study, appears to be a pro-drug with a more suitable pharmacokinetic profile than chartreusin."
01/01/1994 - "Antitumor effects of IST-622, a novel synthetic derivative of chartreusin, against murine and human tumor lines following oral administration."
01/01/1994 - "In addition, IST-622 showed a significant growth-inhibitory effect against two human tumor xenografts, a large-cell lung cancer (Lu-116) and a gastric adenocarcinoma (St-4), among the seven lines tested. "
01/01/1994 - "Following oral administration, IST-622 showed marked antitumor effects against various mouse tumors such as P388 and L1210 leukemias, B16 melanoma, Lewis lung carcinoma, Colon 26 and Colon 38 adenocarcinomas, and M5076 reticulum-cell sarcoma. "
|2.||Breast Neoplasms (Breast Cancer)
06/01/2002 - "Based on the data from 18 patients with breast cancer who were treated orally with 280 or 525 mg/m(2) of IST-622 once daily after breakfast for five consecutive days, we analyzed the relationship between the area under the plasma concentration versus time curve (AUC) and toxicities using a sigmoid E-max model and logistic regression. "
06/01/2002 - "Pharmacokinetic and pharmacodynamic study of IST-622, a novel synthetic derivative of chartreusin, by oral administration in a phase II study of patients with breast cancer."
|3.||Lewis Lung Carcinoma
|5.||Non-Hodgkin Lymphoma (Lymphosarcoma)
|2.||Heterologous Transplantation (Xenotransplantation)